Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.1K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

111
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
111
Lipid Absorption01:24

Lipid Absorption

2.0K
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
2.0K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

3.7K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
3.7K
What are Lipids?01:38

What are Lipids?

215.4K
Overview
215.4K
What are Lipids?01:31

What are Lipids?

9.9K
Lipids function as structural components of cellular membranes, in addition to acting as energy reservoirs and signaling molecules. They are thus crucial to all living organisms.  The three biologically important classes of lipids are triglycerides, phospholipids, and steroids.
Non-Polar and Hydrophobic Characteristics of Lipids
Lipids are a structurally and functionally diverse group of hydrocarbons—compounds consisting of carbon and hydrogen atoms. The carbon-carbon and...
9.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lp(a): A potentially modifiable cardiovascular risk factor.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Assessing pharmacists' knowledge and practices involving dietary supplement omega-3 fatty acids.

Journal of clinical lipidology·2025
Same author

Drug Interactions With Excessive Daytime Sleepiness Treatments.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians·2025
Same author

A narrative review of drugs targeting inflammation in vascular disease.

Postgraduate medicine·2025
Same author

A Clinicians Guide to Recommending Common Cholesterol-Lowering Dietary Supplements.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2024
Same author

Elevated Lp(a): Guidance for Identifying and Managing Patients.

Southern medical journal·2024

Related Experiment Video

Updated: Nov 15, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.9K

New and emerging lipid-lowering therapy.

James M Backes1, Daniel E Hilleman2

  • 1Clinical & Medical Center Affairs, Assistant Director - Atherosclerosis & LDL-Apheresis Center, University of Kansas Medical Center, KU School of Pharmacy, 2010 Becker Drive, Lawrence, KS 66047, USA.

Future Cardiology
|March 1, 2021
PubMed
Summary

New lipid-modifying drugs are emerging to manage dyslipidemias and reduce atherosclerotic cardiovascular disease (ASCVD) risk beyond statins. While small molecules offer potential, biologic agents present complex options for specific patient groups.

Keywords:
apolipoproteinatherosclerosisdyslipidemiahypertriglyceridemialipidsstatins

More Related Videos

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

1.3K
Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.8K

Related Experiment Videos

Last Updated: Nov 15, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.9K
Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

1.3K
Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.8K

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Statins are the primary treatment for atherosclerotic cardiovascular disease (ASCVD).
  • Limitations of statins necessitate the development of novel lipid-modifying agents.
  • Existing therapies face challenges in managing dyslipidemias and reducing ASCVD risk effectively.

Purpose of the Study:

  • To review current and investigational agents for dyslipidemia management.
  • To explore the potential of new small-molecule and biologic drugs in ASCVD risk reduction.
  • To discuss the limitations and future clinical utility of emerging lipid-modifying therapies.

Main Methods:

  • Literature review of current lipid-modifying drugs.
  • Analysis of investigational agents targeting dyslipidemia and ASCVD risk.
  • Evaluation of small-molecule and biologic drug classes in clinical development.

Main Results:

  • Several small-molecule drugs show potential for ASCVD risk mitigation, alone or with statins.
  • Biologic agents, targeting specific enzymes or protein synthesis, dominate clinical development.
  • Biologics have complex mechanisms and manufacturing, with indications for select patient populations.

Conclusions:

  • Investigational agents offer new avenues for managing dyslipidemias and ASCVD risk.
  • Biologic agents present advanced but complex therapeutic options for specific genetic dyslipidemias or refractory cases.
  • The long-term clinical impact of these novel agents will be determined in upcoming years.